What is Proton Therapy

Call Now For More Information

General Questions or
Schedule an Appointment

1-855-528-7248

Current Patients

1-206-306-2800

Physician Line

1-888-987-7782

Ramesh Rengan, MD PhD

“In order to be successful in caring for the patient, a partnership must be forged between the oncologist and the patient, with each contributing to the development of a treatment plan that speaks to all of the needs of the patient.”

Ramesh Rengan, MD PhD

Lung Cancer; Ocular Cancers

Dr. Rengan is a Professor and Chair of the Department of Radiation Oncology at UW Medicine, and a Professor of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, as well as a faculty member of the Immunotherapy Integrated Research Center. He is a board-certified radiation oncologist who specializes in radiation treatment for lung, melanoma, and prostate cancer.

Dr. Rengan was previously the Chief of Thoracic Service and Assistant Director of Clinical Operations for the Department of Radiation Oncology at the University of Pennsylvania, where he worked extensively with proton therapy. He completed his residency in radiation oncology at Memorial Sloan-Kettering Cancer Center in 2006 and earned his medical degree and Ph.D. in biological chemistry from University of Michigan Medical School and Rackham School of Graduate Studies in 2001.

Dr. Rengan’s philosophy of “patients come first” fits well with his areas of research, which involve the development of clinical and translational (bench-to-bedside) initiatives designed to improve clinical outcomes in cancer. His research interests also include understanding the biology of cancer in order to make radiation treatment more effective and using radiation as a tool to stimulate the immune system to target the cancer. 

Accomplishments:

Dr. Rengan serves on many national and international organizations including, the Scientific Advisory Board of the Cancer Terminator Foundation, Particle Therapy Cooperative Oncology Group, American Society for Radiation Oncology (ASTRO), and Cancer Immunotherapy Trials Network Working Group. In 2019, Dr. Rengan was named fellow of ASTRO.